Repligen Corporation Reports Fourth‑Quarter 2025 Results and 2026 Guidance

Repligen Corporation (NASDAQ: RGEN), a life‑sciences company focused on bioprocessing technology, released its financial results for the quarter ended December 31 2025 and issued a forecast for the full year 2026 on February 24 2026.

Fourth‑Quarter 2025 Performance

  • Revenue: $198 million, up 18 % year‑over‑year on reported figures.
  • Organic growth: 14 % in the quarter, driven by continued momentum in orders for Analytics and Proteins solutions.
  • Full‑year 2025 revenue: $738 million, representing a 16 % increase in both reported and organic, non‑COVID growth.

Repligen’s CEO, Olivier Loeillot, highlighted that the company exceeded the high end of its October revenue and adjusted operating income guidance during 2025. He cited traction across the differentiated product portfolio as the key driver of the strong performance and noted ongoing margin expansion.

2026 Financial Guidance

Repligen provided a guidance range for fiscal year 2026:

  • Revenue: $810 million to $840 million, implying 10 %–14 % reported growth and 9 %–13 % organic growth.
  • Adjusted operating margin: An expansion of 150 basis points at the midpoint of the forecast range.

The guidance reflects a continued focus on expanding the commercial presence, scaling operations for agility, and investing in innovation that supports customers’ development timelines and yield improvements.

Strategic Context

Repligen’s product portfolio, encompassing analytics, proteins, and gene‑therapy‑related offerings, underpins its revenue growth. The company’s strategy emphasizes building a stronger commercial footprint and enhancing operational efficiency, with the stated aim of delivering higher margins while supporting clients in accelerating biological drug development.

The company’s market performance as of February 22 2026 shows a close price of $135.40, with a 52‑week high of $175.77 (January 5 2026) and a 52‑week low of $102.97 (April 6 2025). Its market capitalization stands at approximately $7.54 billion.

This article summarizes the financial results and guidance released by Repligen Corporation, drawing exclusively from the information provided in the source materials.